Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 baxdrostat plus dapagliflozin versus placebo plus dapagliflozin in chronic kidney disease with hypertension
MOH_2025-03-04_013954Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and hypertension (HTN) comparing Baxdrostat + dapagliflozin with Placebo + dapagliflozin (2 arms). Primary endpoint: Primary composite renal and cardiovascular outcome. Started Feb 2025; status: recruiting.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on MOH_2025-03-04_013954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-04_013954.